CC Small or few human trials. Promising, not proven. How we grade →Randomized open-label 4-way crossover · 54 overweight adults, single 4 g doses
A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: the ECLIPSE (Epanova compared to Lovaza in a pharmacokinetic single-dose evaluation) study
M Davidson, J Johnson, M Rooney, M Kyle, D Kling. Journal of Clinical Lipidology. 2012.
- In plain language
- ECLIPSE: on a low-fat diet, EPA plus DHA exposure was 4.0 times higher with a free fatty acid drug (Epanova) than with an ethyl ester drug (Lovaza); about 1.3 times on a high-fat diet.
- Limits
- Single doses; open-label; compares two branded drugs; funding not stated in the abstract.
- Which of our grades it feeds
- BB Good human data, but mixed outcomes or surrogate markers. How we grade →Science summary: Omega-3 dose and form: how much EPA and DHA, and does triglyceride vs ethyl ester matter?
- Source
- doi.org/10.1016/j.jacl.2012.01.002 · PubMed 23312053
Summary written by Everstack from the published abstract. Verified against Crossref on 2026-10-15. The authors do not endorse Everstack. We sell some of what we grade.